U.S. FOOD & DRUG ADMINISTRATION

CMC REVIEW MEMORANDUM

Date: December 22, 2021

To: Biologics License Application (BLA) File STN 125742

From: Xiao Wang, CMC Reviewer, OVRR/DVP

Xiao Wang -S (Affiliate) Digitally signed by Xiao Wang -S (Affiliate) DN: c=US o=U.S. Government ou=HHS ou=FDA ou=People 0.9.23 2.19200300.100.1.1=2 00132.822 cn=X ao Wang -S (Affi liate) Date: 2021.12.22 11:33:20 -0500

Through: Anissa Cheung, OVRR/DVP

Anissa M. Cheung -S Dig tally signed by Anissa M. Cheung -S DN: c=US o=U.S. Government ou=HHS ou=FDA ou=People 0.9.23 2.19200300.100.1.1=1300155069 cn=Anissa M. Cheung -S Date: 2021.12.22 11:51: -0500

Applicant: BioNTech Manufacturing GmbH (in partnership with Pfizer Inc.)

Product: COMIRNATY; COVID-19 Vaccine, mRNA (BNT162b2)

Product Type: A Nucleoside-modified Messenger RNA (mRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein, Formulated with Lipids ALC-0315, ALC-0159, DSPC, and Cholesterol to form Lipid Nanoparticles (LNPs)

STN: BLA STN 125742/11

Subject: Product Correspondence;
To Correct the (b) (4) from (b) (4) to (b) (4)

Action due date: NA

Recommendation: No Further Action

Summary of Product Correspondence

During the review of the original BLA 125742/0 for COMIRNATY, an information request (IR) regarding the (b) (4) operation was issued to the applicant on August 17, 2021 (shown below).

> *In your drug substance (DS) manufacturing process validation studies performed at both Pfizer* (b) (4) *and Pfizer* (b) (4) *the process parameter for the* (b) (4) (b) (4) *was validated to be within the range of* (b) (4) *. However, in your documents Section 3.2.S.2.2 Manufacturing Process Andover and Section 3.2.S.2.4 Controls of Critical Steps and Intermediates - Manufacturing Process, the* (b) (4) *is described as* (b) (4) *. Please align the acceptance range of this process control parameter in all the documents based on your validation study results.*

On August 18, 2021, the applicant provided relevant supporting information via email indicating that the (b) (4) was studied as a (b) (4) (b) (4) experiment with a range of (b) (4) . The study results demonstrated that the full range of the (b) (4) gave acceptable results, (b) (4)

Based on the above explanation, CBER emailed the applicant on August 19, 2021 and stated that the PAR of (b) (4) is acceptable. On August 19, 2021, however, the applicant submitted a change to the (b) (4) (b) (4) from (b) (4) to (b) (4) in amendment STN 125742/0.62. As the proposed change was within the approved PAR for (b) (4), no action was taken at the time.

In the present "Product Correspondence" submission, the applicant is making corrections to change the (b) (4) from (b) (4) back to the previously approved (b) (4) in the following three documents:

- 3.2.S.2.2 Description of Manufacturing Process and Process Controls [Andover]
- 3.2.S.2.4 Control of Critical Steps and Intermediates
- 3.2.S.2.6 Manufacturing Process Development – Process Development and Characterization

Reviewer's Comment:

The change made for the (b) (4) is considered acceptable. No further action indicated.